KSKodai Sakiyama

Kodai Sakiyama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kodai Sakiyama has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Michihito Kono

    Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University

    4 shared publications
  • Tatsuya Atsumi

    Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan

    4 shared publications
  • Masaru Kato

    The First Department of Internal Medicine, Faculty of Medicine, University of Toyama , Toyama

    3 shared publications
  • Maria Tada

    Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo

    2 shared publications
  • Mitsutaka Yasuda

    Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo

    2 shared publications
  • Olga Amengual

    Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo

    2 shared publications

Latest Publications

  • A Woman with Progressive Skin Ulceration

    by Kodai Sakiyama, Hiroyuki Yano, Mitsuyo Kinjo

  • Open Access

    Consolidation volume assessed by quantitative computed tomography predicts the prognosis of pneumocystis pneumonia in rheumatic diseases

    by Kodai Sakiyama, Ryo Hisada, Mitsutaka Yasuda, Maria Tada, Yotaro Oki, Masanari Sugawara, Yuka Shimizu, Shuhei Shimoyama, Shuhei Takeyama, Tetsuya Horita, et al.

    Objectives: To investigate the prognostic value of quantitative computed tomography (QCT) analysis in pneumocystis pneumonia (PCP) patients with rheumatic diseases, specifically relating abnormal lung volumes (ALV) to major clinical events (MCE). Methods: This multicentre, retrospective study included 83 PCP patients with rheumatic diseases. QCT automatically quantified ALV, categorized into consolidation (≥ −300 HU) and ground-glass opacities (< −300 HU). The primary outcome was MCE, including intubation, intensive care unit admission and death. Logistic regression and survival analyses assessed associations between QCT-derived volumes and MCE. Results: MCE occurred in 17 patients (20%). Patients with MCE had significantly larger consolidation volumes than those without MCE (median, 5.7% vs 0.4%, P < 0.001). Logistic regression analysis identified lactate dehydrogenase, C-reactive protein and beta-D-glucan as risk factors; however, consolidation volume remained independently associated with MCE after adjustment (odds ratio: 1.33, 95% confidence interval 1.11–1.59, P < 0.001). Receiver operating characteristic analysis of consolidation volume for predicting MCE showed an area under the curve of 0.89 (P < 0.001). Kaplan–Meier analysis revealed significantly lower MCE-free survival in patients with consolidation volumes ≥1.4% (P < 0.001; log-rank test). Conclusions: In PCP patients with rheumatic diseases, QCT-derived consolidation volume is a strong predictor of severe outcomes.

  • Open Access

    Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue With Spontaneous Shrinkage in a Patient With Sjögren Syndrome

    by Kodai Sakiyama, Michihito Kono, Ai Shimizu, Tatsuya Atsumi

    Patients with Sjögren syndrome (SS) have a higher risk of developing malignant lymphoma.1 A 68-year-old woman presented with a 2-month history of swollen parotid glands. The patient had psoriatic arthritis and had been treated with secukinumab for 3 months.


  • The chest CT signs for pulmonary veno-occlusive disease correlate with pulmonary haemodynamics in systemic sclerosis

    by Haruka Moriya, Masaru Kato, Ryo Hisada, Keita Ninagawa, Maria Tada, Kodai Sakiyama, Mitsutaka Yasuda, Michihito Kono, Yuichiro Fujieda, Olga Amengual, et al.

    Objectives: Pulmonary arterial hypertension associated with systemic sclerosis (PAH-SSc) sometimes accompanies pulmonary veno-occlusive disease (PVOD). We aimed to reveal the relationship between clinical signs of PVOD and severity of pulmonary vasculopathy in SSc. Methods: This study included 52 consecutive SSc patients who had pulmonary haemodynamic abnormalities [mean pulmonary arterial pressure (mPAP) >20 mmHg, pulmonary vascular resistance >2 WU or pulmonary artery wedge pressure (PAWP) >15 mmHg]. A chest CT scan was evaluated in all patients. Patients were divided into two groups, the 0–1 group and the 2–3 group, according to the number of chest CT signs for PVOD, including mediastinal lymph node enlargement, thickened interlobular septal wall and ground glass opacity. Pulmonary haemodynamics, echocardiography and MRI-based cardiac function, pulmonary function and serum biomarkers were compared between the two groups. Results: Mediastinal lymph node enlargement, thickened interlobular septal wall and ground glass opacity were observed in 11 (21%), 32 (62%) and 11 (21%) patients, respectively. The 2–3 group (n = 15) had higher mPAP (P = 0.02) but lower diffusing capacity of carbon monoxide (DLCO)/alveolar volume (P = 0.02) compared with the 0–1 group (n = 37). Other parameters, including PAWP, cardiac output, left ventricular ejection fraction, left atrial diameter, forced vital capacity, brain natriuretic peptide and Krebs von den Lunge-6 were not different between the two groups. Conclusions: The CT signs for PVOD had a positive correlation with mPAP but a negative correlation with DLCO in SSc patients, indicating that PAH-SSc may reflect a spectrum of pulmonary vascular disease that ranges from the pulmonary artery to the vein.


  • Top Cited Papers
    Open Access

    Itaconate ameliorates autoimmunity by modulating T cell imbalance via metabolic and epigenetic reprogramming

    by Kuniyuki Aso, Michihito Kono, Masatoshi Kanda, Yuki Kudo, Kodai Sakiyama, Ryo Hisada, Kohei Karino, Yusho Ueda, Daigo Nakazawa, Yuichiro Fujieda, et al.

    Dysregulation of Th17 and Treg cells contributes to the pathophysiology of many autoimmune diseases. Herein, we show that itaconate, an immunomodulatory metabolite, inhibits Th17 cell differentiation and promotes Treg cell differentiation by orchestrating metabolic and epigenetic reprogramming. Mechanistically, itaconate suppresses glycolysis and oxidative phosphorylation in Th17- and Treg-polarizing T cells. Following treatment with itaconate, the S-adenosyl-L-methionine/S-adenosylhomocysteine ratio and 2-hydroxyglutarate levels are decreased by inhibiting the synthetic enzyme activities in Th17 and Treg cells, respectively. Consequently, these metabolic changes are associated with altered chromatin accessibility of essential transcription factors and key gene expression in Th17 and Treg cell differentiation, including decreased RORγt binding at the Il17a promoter. The adoptive transfer of itaconate-treated Th17-polarizing T cells ameliorates experimental autoimmune encephalomyelitis. These results indicate that itaconate is a crucial metabolic regulator for Th17/Treg cell balance and could be a potential therapeutic agent for autoimmune diseases.